BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37877146)

  • 1. Upregulation of M6A Reader HNRNPA2B1 Associated with Poor Prognosis and Tumor Progression in Lung Adenocarcinoma.
    Wang W; Li S
    Recent Pat Anticancer Drug Discov; 2023 Oct; ():. PubMed ID: 37877146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HNRNPA2B1 inhibited SFRP2 and activated Wnt-β/catenin via m6A-mediated miR-106b-5p processing to aggravate stemness in lung adenocarcinoma.
    Rong L; Xu Y; Zhang K; Jin L; Liu X
    Pathol Res Pract; 2022 May; 233():153794. PubMed ID: 35364458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma.
    Zhang Y; Liu X; Liu L; Li J; Hu Q; Sun R
    Med Sci Monit; 2020 Feb; 26():e919644. PubMed ID: 32086933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIAA1429 promotes the progression of lung adenocarcinoma by regulating the m6A level of MUC3A.
    Zhao W; Xie Y
    Pathol Res Pract; 2021 Jan; 217():153284. PubMed ID: 33249400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner.
    Hao W; Chen Z; Tang J; Yang R; Gao WQ; Xu H
    J Transl Med; 2023 Nov; 21(1):861. PubMed ID: 38017546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HNRNPA2B1-mediated m6A modification of FOXM1 promotes drug resistance and inhibits ferroptosis in endometrial cancer via regulation of LCN2.
    Jiang J; Zhu J; Qiu P; Ni J; Zhu W; Wang X
    Funct Integr Genomics; 2023 Dec; 24(1):3. PubMed ID: 38091112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. m
    Wu H; Xu H; Huang S; Tang Y; Tang J; Zhou H; Xie L; Qiao G
    Front Oncol; 2022; 12():989817. PubMed ID: 36249006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF2BP3 is an essential N
    Xu X; Cui J; Wang H; Ma L; Zhang X; Guo W; Xue X; Wang Y; Qiu S; Tian X; Miao Y; Wu M; Yu Y; Xu Y; Wang J; Qiao Y
    Mater Today Bio; 2022 Dec; 17():100503. PubMed ID: 36457846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the HNRNPA2B1/
    Sun M; Shen Y; Jia G; Deng Z; Shi F; Jing Y; Xia S
    J Cancer; 2023; 14(7):1242-1256. PubMed ID: 37215455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of miR-30c-5p as a tumor suppressor by targeting the m
    Wu Q; Li G; Gong L; Cai J; Chen L; Xu X; Liu X; Zhao J; Zeng Y; Gao R; Yu L; Wang Z
    Cancer Med; 2023 Feb; 12(4):5055-5070. PubMed ID: 36259156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. circ_0000567/miR-421/
    Hong Y; Si J; Xiao B; Xiong Y; Dai C; Yang Y; Li S; Ma Y
    J Cancer; 2022; 13(5):1540-1552. PubMed ID: 35371319
    [No Abstract]   [Full Text] [Related]  

  • 12.
    Wu C; Dong B; Huang L; Liu Y; Ye G; Li S; Qi Y
    Front Oncol; 2021; 11():754290. PubMed ID: 34745988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and immune infiltrative biomarkers of CENPO in pan-cancer and its relationship with lung adenocarcinoma cell proliferation and metastasis.
    Wang Y; Ye D; Li Y; Lv F; Shen W; Li H; Tian L; Fan Z; Li Y; Wang Y; Li F; Chen Y
    BMC Cancer; 2023 Aug; 23(1):735. PubMed ID: 37558987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit-induced long intergenic non-protein coding RNA 1833 N6-methyladenosine methylation promotes the non-small cell lung cancer progression via regulating heterogeneous nuclear ribonucleoprotein A2/B1 expression.
    Li D; Fu Z; Dong C; Song Y
    Bioengineered; 2022 Apr; 13(4):10493-10503. PubMed ID: 35441574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. m
    Wang H; Zhao X; Lu Z
    Front Genet; 2021; 12():622233. PubMed ID: 33643384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of keratin 6C is associated with poor prognosis and accelerates cancer proliferation and migration by modulating epithelial-mesenchymal transition in lung adenocarcinoma.
    Hu HB; Yang XP; Zhou PX; Yang XA; Yin B
    Genes Genomics; 2020 Feb; 42(2):179-188. PubMed ID: 31768767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of m6A modification patterns and m6A-related lncRNAs as potential biomarkers in lung adenocarcinoma.
    Wang S; Gu X; Xu D; Liu B; Qin K; Yuan X
    Environ Toxicol; 2024 Apr; 39(4):2285-2303. PubMed ID: 38148718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HNRNPA2B1-mediated m
    Li K; Gong Q; Xiang XD; Guo G; Liu J; Zhao L; Li J; Chen N; Li H; Zhang LJ; Zhou CY; Wang ZY; Zhuang L
    J Transl Med; 2023 Jun; 21(1):382. PubMed ID: 37308993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-Binding Protein IGF2BP1 Associated With Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
    Liu J; Li Z; Cheang I; Li J; Zhou C
    Front Genet; 2022; 13():777399. PubMed ID: 35154270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Heterogeneous Nuclear Ribonucleoprotein C Expression Correlates With Poor Prognosis in Patients With Surgically Resected Lung Adenocarcinoma.
    Guo W; Huai Q; Zhang G; Guo L; Song P; Xue X; Tan F; Xue Q; Gao S; He J
    Front Oncol; 2020; 10():598437. PubMed ID: 33569346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.